Traders should monitor the March 31 earnings call for financial clarity and any updates on cash runway, R&D spend, or clinical trial progress. The C-Further/Southampton collaboration adds strategic value but does not materially alter near-term financials.
INKT drugs
INKT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 17 $9.57entry
- T+1 · 8mo ago −1.15%α +0.25% · $9.46
- T+5 · 8mo ago −10.55%α −7.90% · $8.56
- T+20 · 7mo ago +35.21%α +30.91% · $12.94
- T+60 · 5mo ago +23.51%α +13.65% · $11.82
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
MiNK Therapeutics announced it will report Q4 and full-year 2025 financial results on March 31, 2026, alongside a corporate update on clinical progress and its iNKT cell therapy platform. The press release highlights a new collaboration with C-Further and the University of Southampton to develop a PRAME-targeted iNKT therapy for pediatric cancers, bringing non-dilutive funding and strategic validation. However, no actual financial data was disclosed in this announcement.
Key Facts
- MiNK Therapeutics will report Q4 and full-year 2025 financial results on March 31, 2026, before market open.
- Company to host a conference call at 8:30 a.m. ET to discuss results and provide a corporate update.
- New collaboration with C-Further and University of Southampton on a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers.
- Collaboration includes non-dilutive funding and potential downstream commercial revenue.
- No financial results (revenue, EPS, cash position) were released in this announcement.
Financial Impact
No financial data disclosed, impact deferred to earnings release
Risk Factors
- No financial metrics provided, actual results could miss expectations.
- High cash burn typical for clinical-stage biotechs; funding needs could emerge if partnerships don't scale.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257040 |
Track record
21 reports on INKT
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers